title: Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
authors.affiliation: Department of Medical Oncology, Izmir University Medical Park Hospital, Izmir, Turkey. arslancagatay@yahoo.com.
authors.forename: Cagatay
authors.initials: C
authors.lastname: Arslan
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000736:Androstenes / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000008:administration & dosage / Q000031:analogs & derivatives; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000726:Androgen Antagonists; D000736:Androstenes; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D043823:Taxoids; D000077143:Docetaxel; D010669:Phenylthiohydantoin; C552428:cabazitaxel; C540278:enzalutamide; C089740:abiraterone